Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00989586 · OUTCOME

Access Pharmacokinetics Through Cmax

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · Source last updated 2017-02-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ug/ml
Interval / dispersion
Standard Deviation
Time frame
0, 24, 48, 72, 96 and 120 hours post-dose

What was measured

Evaluation of pharmacokinetics of veltuzumab and milatuzumab was performed for patients included in the trial. Statistically, descriptive data of PK parameters will be computed. Relationships between such parameters as dose and AUC, volume of distribution, clearance, and others will be evaluated, but be preliminary due to the small sample size.

Analysis population: Cmax for patients dosed at 20 mg/kg

Groups in this outcome

Patients Dosed at 20mg/kg

First dose milatuzumab pharmacokinetics for patients doses at 20 mg/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Patients Dosed at 20mg/kg17

Reported measurements

Source class 1
Values in ug/ml · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Patients Dosed at 20mg/kg480116Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        116
        value
        480
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
Evaluation of pharmacokinetics of veltuzumab and milatuzumab was performed for patients included in the trial. Statistically, descriptive data of PK parameters will be computed. Relationships between such parameters as dose and AUC, volume of distribution, clearance, and others will be evaluated, but be preliminary due to the small sample size.
dispersion Type
Standard Deviation
groups
  1. description
    First dose milatuzumab pharmacokinetics for patients doses at 20 mg/kg
    id
    OG000
    title
    Patients Dosed at 20mg/kg
param Type
MEAN
population Description
Cmax for patients dosed at 20 mg/kg
reporting Status
POSTED
time Frame
0, 24, 48, 72, 96 and 120 hours post-dose
title
Access Pharmacokinetics Through Cmax
type
SECONDARY
unit Of Measure
ug/ml

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice